SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-24-000601
Filing Date
2024-05-07
Accepted
2024-05-07 07:10:40
Documents
71
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20240331x10q.htm   iXBRL 10-Q 1284580
2 EX-31.1 tmb-20240331xex31d1.htm EX-31.1 15652
3 EX-32.1 tmb-20240331xex32d1.htm EX-32.1 7279
4 GRAPHIC tmb-20240331x10q001.jpg GRAPHIC 53190
  Complete submission text file 0001410578-24-000601.txt   6233509

Data Files

Seq Description Document Type Size
5 EX-101.SCH tmb-20240331.xsd EX-101.SCH 47984
6 EX-101.CAL tmb-20240331_cal.xml EX-101.CAL 54467
7 EX-101.DEF tmb-20240331_def.xml EX-101.DEF 186088
8 EX-101.LAB tmb-20240331_lab.xml EX-101.LAB 411229
9 EX-101.PRE tmb-20240331_pre.xml EX-101.PRE 307123
75 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20240331x10q_htm.xml XML 1006304
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

IRS No.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12584 | Film No.: 24919583
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)